- Home
- VTYX vs JYNT Comparison
VTYX vs JYNT Comparison
Compare VTYX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- JYNT
- Stock Information
- Founded
- VTYX 2018
- JYNT 2010
- Country
- VTYX United States
- JYNT United States
- Employees
- VTYX N/A
- JYNT N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- JYNT Multi-Sector Companies
- Sector
- VTYX Health Care
- JYNT Miscellaneous
- Exchange
- VTYX Nasdaq
- JYNT Nasdaq
- Market Cap
- VTYX 154.9M
- JYNT 172.8M
- IPO Year
- VTYX 2021
- JYNT 2014
- Fundamental
- Price
- VTYX $1.61
- JYNT $11.35
- Analyst Decision
- VTYX Buy
- JYNT Strong Buy
- Analyst Count
- VTYX 4
- JYNT 2
- Target Price
- VTYX $11.33
- JYNT $17.50
- AVG Volume (30 Days)
- VTYX 1.3M
- JYNT 28.8K
- Earning Date
- VTYX 03-04-2025
- JYNT 03-13-2025
- Dividend Yield
- VTYX N/A
- JYNT N/A
- EPS Growth
- VTYX N/A
- JYNT N/A
- EPS
- VTYX N/A
- JYNT N/A
- Revenue
- VTYX N/A
- JYNT $120,795,620.00
- Revenue This Year
- VTYX N/A
- JYNT $3.28
- Revenue Next Year
- VTYX N/A
- JYNT N/A
- P/E Ratio
- VTYX N/A
- JYNT N/A
- Revenue Growth
- VTYX N/A
- JYNT 5.26
- 52 Week Low
- VTYX $1.57
- JYNT $9.10
- 52 Week High
- VTYX $11.48
- JYNT $17.82
- Technical
- Relative Strength Index (RSI)
- VTYX 34.49
- JYNT 52.34
- Support Level
- VTYX $1.57
- JYNT $11.29
- Resistance Level
- VTYX $1.78
- JYNT $11.98
- Average True Range (ATR)
- VTYX 0.10
- JYNT 0.33
- MACD
- VTYX -0.00
- JYNT -0.03
- Stochastic Oscillator
- VTYX 10.26
- JYNT 47.06
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.